Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06770530

Introduction of Mycotic Prophylaxis At Cystectomy Trial.

This study aims to introduce a perioperative antifungal prophylaxis for patients undergoing cystectomy: surgically removal of the urinary bladder with construction of a urinary diversion. We wish to investigate the effect of antifungal prophylaxis on complications after the operation.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Department of Urology, Rigshospitalet

Copenhagen, 2100, Denmark

Location status: Recruiting

Location contact

Adreas Røder, MD, PhD, Professor

CONTACT

[email protected]

+4535458789

About this study

Cystectomy with construction of a urinary diversion, is a major cancer surgery and one of the most complex surgeries in the urological specialty. After cystectomy, the most commonly performed urinary diversion is an ileal conduit, where a section of the terminal ileum is shunted out and connected to the upper urinary tract and a stoma is created. During this procedure, the abdominal cavity is exposed to bacteria and fungus from the ileum. Besides the perioperative contamination, micro-leakage in relation to the anastomosis is suspected to contribute to a local infectious response that may result in postoperative complications as ileal paralysis. Paralytic ileus is a serious complication that affects many patients after cystectomy, resulting in a prolonged length of stay, low quality of life postoperatively, and increased risk of complications such as aspiration, pneumonia, wound rupture, deep venous thrombosis, undernourishment and infections.

Current guidelines support the use of perioperative antibiotics targeting gram-negative and gram-positive bacteria, typically administered as broad-spectrum medicine such as piperacillin/tazobactam or cephalosporins. Regarding fungal infections, emerging data show that 48% of the patients undergoing RC have candida albicans in samples from the terminal ileum. Also, it is well known that fungal infections are highly prevalent in patients undergoing gastrointestinal surgery where it is associated with a high risk of mortality.

Small retrospective studies suggest that the addition of antifungal medicine to perioperative antibiotics can reduce the risk of bowel- and infectious complications after abdominal surgery.

The compelling theoretical and clinical rationale for addition of antifungal prophylaxis to standard-of-care antibiotic prophylaxis for patients undergoing radical cystectomy provides the basis for initiation of a randomized clinical trial representing the highest level of evidence.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients 18 years and older
  • Willingness to participate in the study and the ability to understand and sign an informed consent
  • Indication for performing cystectomy
  • The urinary diversion is limited to the ileal conduit

Exclusion criteria

  • Patients with contraindications to Fluconazole. This includes allergies and treatment with non-pausable medication that in combination is contraindicated
  • Patients in active treatment for mycotic infections

Treatment and study plan

Fluconazole

Drug

400 mg inravenous Fluconazole, single dose 200 ml

Isotonic saline solution

Drug

Intravenous saline solution, single dose 200 ml

Primary outcomes

  1. Postoperative complications

    Time frame: 90 days from surgery

    Measured by Clavien Dindo III-V classification score. The Clavien Dindo Classification is used to rank the severity of a surgical complication. It consists of seven grades (I, II, IIIa, IIIb, IVa, IVb, V) with I being any deviation from the normal postoperative course and V being death of a patient.

Secondary outcomes

  1. Days Alive and Out of Hospital (DAOH)

    Time frame: 90 days from surgery

    Number of days alive and out of hospital within 90 days from surgery

  2. Time to gastrointestinal function

    Time frame: Postoperatively within 90 days

    First bowel movement

  3. Nasogastric tube placement

    Time frame: Postoperatively within 90 days

    Number of nasogastric tube placements

  4. Length of stay (LOS)

    Time frame: 90 days from surgery

    Duration (days) of primary hospitalization.

  5. Readmission rate

    Time frame: 90 days after surgery

    Number of readmissions

  6. Quality of life (QoL): EORTC QLQ-C30

    Time frame: Before operation and 90 days after surgery

    Questionnaire from EORTC: European Organization for Research and Treatment of Cancer. All of the scales and single-item measures range in score from 0 to 100. The questionnaires consists of a global health status (high score represents high quality of life), a functional scale (a high score represents a high/healthy level of functioning) and a symptom scale (a high score represents a high level of symptomatology/problems).

  7. Quality of Life(QOL): EORTC QLQ-BLM30

    Time frame: Before operation and 90 days after

    Questionnaire from EORTC: European Organization for Research and Treatment of Cancer. All of the scales and single-item measures range in score from 0 to 100. The questionnaires consists of a global health status (high score represents high quality of life), a functional scale (a high score represents a high/healthy level of functioning) and a symptom scale (a high score represents a high level of symptomatology/problems).

Study contacts

Contact information is provided by the study sponsor or research team.

Mie Ynddal, MD

CONTACT

[email protected]

+4535456152

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Registry information

Official study title

IMPACT - the Introduction of Mycotic Prophylaxis At Cystectomy Trial. Perioperative Mycotic Prophylaxis to Reduce Postoperative Complications Following Cystectomy - a Double-blinded, Placebo-controlled, Randomized Trial

Acronym: IMPACT

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Jan 13, 2025
Registry last updated
Jan 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.